2. Signaling Pathways
  3. Anti-infection
    Metabolic Enzyme/Protease
  4. HCV Protease

HCV Protease

HCV Protease

Related Products

PDF 0.2 MB

HCV NS3-4A serine protease is a complex composed of NS3 and its cofactor NS4A. It harbours serine protease as well as NTPase/RNA helicase activities and is essential for viral polyprotein processing, RNA replication and virion formation.

The HCV NS3/4A protease efficiently cleaves and inactivates two important signaling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce interferons (IFNs), i.e., mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF). HCV infection is associated with chronic liver disease, including hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma. The NS3-4A serine protease of HCV has been one of the most attractive targets for developing specific antiviral agents against HCV.

HCV Protease Related Products (85):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-108060A
    Valopicitabine dihydrochloride
    		Inhibitor 99.04%
    Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination.
    Valopicitabine dihydrochloride
  • HY-12946
    BI 653048
    		Inhibitor 99.84%
    BI 653048, a chemical probe, is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM). BI 653048 (Compound 103) is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus.
    BI 653048
  • HY-19558
    IDX184
    		Inhibitor 99.80%
    IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM).
    IDX184
  • HY-16784
    Samatasvir
    		Inhibitor 99.39%
    Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons.
    Samatasvir
  • HY-30234
    Clemizole
    		Inhibitor 98.42%
    Clemizole is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. Clemizole is an inhibitor of TRPC5 channel. The IC50 of Clemizole for RNA binding by NS4B is 24±1 nM, whereas its EC50 for viral replication is 8 µM.
    Clemizole
  • HY-109571
    HZ-1157
    		Inhibitor 98.16%
    HZ-1157 inhibits HCV NS3/4A protease with an IC50 of 1.0 μmol/L. HZ-1157 (4a) has a high dengue virus inhibitory activity (EC50 = 0.15 μM) and is a relatively nontoxic (CC50 > 10 μM) dengue antiviral agent.
    HZ-1157
  • HY-W033815
    6-Chloroindole-2-carboxylic acid
    6-Chloroindole-2-carboxylic acid (Compound 10g) is a derivative of 2-carboxyindole. 6-Chloroindole-2-carboxylic acid can bind to the hepatitis C virus NS3 protease/NS4A cofactor complex, and its KD value for the ns4a-ns3p protein is 0.4 mM.
    6-Chloroindole-2-carboxylic acid
  • HY-10243
    Vaniprevir
    		Inhibitor 99.60%
    Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
    Vaniprevir
  • HY-10241A
    Simeprevir sodium
    		Inhibitor
    Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.
    Simeprevir sodium
  • HY-108060
    Valopicitabine
    		Inhibitor
    Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination.
    Valopicitabine
  • HY-N1341
    Roseoside
    		Inhibitor
    Roseoside is an inhibitor of DNA gyrase and HAV 3C protease, and also inhibits HCV NS5A/B replicase in human systems with an IC50 of 20 μM. Roseoside binds to the active site of enzymes and stabilizes the interaction by forming hydrogen bonds with key amino acid residues. Roseoside inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, and interferes with HCV RNA replication in vitro by inhibiting HCV NS5A/B replicase (IC50=20 μM). Roseoside shows no cytotoxicity and serves as a research tool for studies related to bacterial infections, candidiasis, HAV and HCV.
    Roseoside
  • HY-19643
    JTK-109
    		Inhibitor 98.68%
    JTK-109 is a potent inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase. JTK-109 has NS5B inhibitory activity with IC50 value of 0.017μM. JTK-109 can be used for the research of hepatitis C virus (HCV) .
    JTK-109
  • HY-145335
    GSK2818713
    		Inhibitor
    GSK2818713 is a novel Hepatitis C NS5A replication complex inhibitor.
    GSK2818713
  • HY-126973
    BI-1230
    		Inhibitor
    BI-1230, a chemical probe, is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication. BI-1230 is also highly selective against other serine/cysteine proteases. BI-1230 shows good Pharmacokinetic(PK) activity.
    BI-1230
  • HY-131905S
    BMS-986144
    		Inhibitor
    BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection.
    BMS-986144
  • HY-12594A
    Paritaprevir dihydrate
    		Inhibitor
    Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor).
    Paritaprevir dihydrate
  • HY-117411
    Coblopasvir
    		Inhibitor
    Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection.
    Coblopasvir
  • HY-P2502
    Hepatitis Virus C NS3 Protease Inhibitor 2
    		Inhibitor
    Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM.
    Hepatitis Virus C NS3 Protease Inhibitor 2
  • HY-10237S
    Boceprevir-d9
    		Inhibitor
    Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
    Boceprevir-d<sub>9</sub>
  • HY-15256S1
    Faldaprevir-d7
    Faldaprevir-d7 is deuterium labeled Faldaprevir.
    Faldaprevir-d<sub>7</sub>